Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma

Background: Colorectal cancer is one of the most commonly diagnosed cancers and cancer- related death worldwide. Identification of new specific biomarkers could be helpful to detection of this malignancy. Altered plasma microRNA expression has been identified in many cancers, including colorectal cancer. Objectives: The main objective of this study was to identify the circulating microRNAs with the most expression changes in colorectal cancer patients compared with neoplasm free healthy individuals. Materials and Methods: MicroRNA expression profiling was performed on plasma samples of 37 colorectal cancer patients and 8 normal subjects using microRNA microarray. Quantitative real-time reverse transcription polymerase chain reaction was used to validate the two selected altered microR NAs. Plasma samples from 61 colorectal cancer patients and 24 normal subjects were used in our validation study. Results: In profiling study we found a panel of six plasma microRNAs with significant downregulation. MicroRNA-142-3p and microRNA-26a-5p were selected and validated by polymerase chain reaction. Our results demonstrated that expression levels of plasma microRNA-142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group. Conclusions: Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.

[1]  S. Horita,et al.  Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4 , 2014, Cancer medicine.

[2]  Ming Sun,et al.  Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer , 2014, Molecular Cancer.

[3]  P. Leedman,et al.  miR-331-3p regulates expression of neuropilin-2 in glioblastoma , 2013, Journal of Neuro-Oncology.

[4]  D. Shi,et al.  MicroRNA-142-3p is frequently upregulated in colorectal cancer and may be involved in the regulation of cell proliferation , 2013, Chinese Science Bulletin.

[5]  G. Fu,et al.  MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells , 2013, Journal of Molecular Medicine.

[6]  Shucheng Ma,et al.  Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma , 2013, Medical Oncology.

[7]  Kshitij Srivastava,et al.  Comprehensive Review of Genetic Association Studies and Meta-Analyses on miRNA Polymorphisms and Cancer Risk , 2012, PloS one.

[8]  J. Błasiak,et al.  The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. , 2012, Acta biochimica Polonica.

[9]  V. Marquez,et al.  MicroRNA-26a is Strongly Down-regulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD) , 2012, The Journal of investigative dermatology.

[10]  Mark P Purdue,et al.  Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. , 2012, The New England journal of medicine.

[11]  K. Robertson,et al.  Abstract 17: Tumor-suppressive function of SLC5A8 in renal cancer cells , 2012 .

[12]  W. Mustain,et al.  Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. , 2012, Cancer research.

[13]  A. Ma,et al.  MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. , 2012, Cancer genetics.

[14]  A. Zauber,et al.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. , 2012, The New England journal of medicine.

[15]  Young C. Lin,et al.  Abstract 33: Microarray analysis of zeranol induced gene expression in primary cultured human breast cancer epithelial cells , 2011 .

[16]  A. Singh,et al.  MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. , 2010, Molecular and cellular pharmacology.

[17]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[18]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.

[19]  A. Barker,et al.  miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer* , 2009, The Journal of Biological Chemistry.

[20]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[21]  Wei Shi,et al.  Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues , 2009, Laboratory Investigation.

[22]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[23]  J. Cayuela,et al.  First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia , 2008 .

[24]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[25]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[26]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[27]  P. Glasziou,et al.  Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An Update , 2008, The American Journal of Gastroenterology.

[28]  William Ignace Wei,et al.  Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue , 2008, Clinical Cancer Research.

[29]  T. Leung,et al.  Detection and characterization of placental microRNAs in maternal plasma. , 2008, Clinical chemistry.

[30]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[31]  M. Pencina,et al.  Exhaled carbon monoxide with waterpipe use in US students. , 2008, JAMA.

[32]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[33]  J. Coller,et al.  Faculty Opinions recommendation of Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. , 2007 .

[34]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[35]  E. Wiemer,et al.  miRNAs and cancer , 2006, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[36]  Minchen Chien,et al.  Prognostic Values of microRNAs in Colorectal Cancer , 2006, Biomarker insights.

[37]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[38]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[39]  P. Delvenne,et al.  Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers , 2003, British Journal of Cancer.

[40]  E. Bandrés,et al.  miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. , 2013, Bone.

[41]  Zhenlin Zhang,et al.  A novel VCP mutation as the cause of atypical IBMPFD in a Chinese family. , 2013, Bone.

[42]  Lu Wang,et al.  MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. , 2011, Cancer research.

[43]  Bo Zhang,et al.  Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. , 2011, Carcinogenesis.

[44]  Ying Chen,et al.  MiR-26 a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH 2 , 2010 .

[45]  P. Boutros,et al.  Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues , 2009, Laboratory Investigation.

[46]  N. Dubrawsky.  Cancer statistics , 2022 .